Mice tumor free and protected from metastases after treatment
The shells of a common plant virus, inhaled into a lung tumor or injected into ovarian, colon or breast tumors, not only triggered the immune system in mice to wipe out the tumors, but provided systemic protection against metastases, researchers from Case Western Reserve University and Dartmouth University report.
The scientists tested a 100-year-old idea called in-situ vaccination. The idea is to put something inside a tumor and disrupt the environment that suppresses the immune system, thus allowing the natural defense system to attack the malignancy.
That something–the hard coating of cowpea mosaic virus–caused no detectible side effects, which are a common problem with traditional therapies and some immunotherapies.
The team’s research is published in the journal Nature Nanotechnology.
“The cowpea virus-based nanoparticles act like a switch that turns on the immune system to recognize and fight against the tumor – as well as to remember it,” said Nicole Steinmetz, an assistant professor of biomedical engineering at Case Western Reserve, appointed by the Case Western Reserve School of Medicine.
“The particles are shockingly potent,” said Steven Fiering, professor of microbiology and immunology at Dartmouth’s Geisel School of Medicine. “They’re easy to make and don’t need to carry antigens, drugs or other immunostimmulatory agents on their surface or inside.”
The professors studied the nanoparticles with Dartmouth’s Pat Lizotte, a molecular and cellular biology PhD student; Mee Rie Sheen, a postdoctoral fellow; and Pakdee Rojanasopondist, an undergraduate student; and Case Western Reserve’s Amy Wen, a biomedical engineering PhD student.
Taking another shot
The immune system’s ability to detect and destroy abnormal cells is thought to prevent many cancers, according to the National Cancer Institute. But when tumors start to develop, they can shut down the system, allowing tumors to grow and spread.
To restart immune defenses, the scientists used the tumor itself as if it were the antigen in a vaccine–that is, the target for antibodies produced by the immune system.
The cowpea virus shell, with its infectious components removed, acts as the adjuvant–a substance that triggers and may enhance or prolong antigen-specific immune responses.
The process and results
The researchers first switched on the immune system in mice to attack B16F10 lung melanoma or skin melanoma, leaving the mice tumor-free. When the treated mice were later injected with B16F10 skin melanoma (to re-challenge the cured mice), four out of five mice were soon cancer free and one had a slow-growing tumor.
The nanoparticles proved effective against ovarian, breast and colon tumor models. Most of the tumors deteriorated from the center and collapsed. The systemic response prevented or attacked metastatic disease, which is the deadliest form of cancer.
“You get benefits against disease you don’t even know is there yet,” Fiering said.
“Because everything we do is local, the side effects are limited,” despite the strength and extent of the immune response, Fiering said. No toxicity was found.
Harsh side effects, such as fatigue, pain, flu-like symptoms and more are common with chemo and radiation therapies and with some immunostimulation drugs.
The researchers are now trying to understand how the virus shell stimulates the immune system.
“It’s not cytotoxic, there’s no RNA involved or lipopolysaccharides that may be used as adjuvants, and it’s not simply an irritant,” Steinmetz said. “We see a specific immune response.”
The Latest on: Immune response against cancer
via Google News
The Latest on:Iimmune response against cancer
- All gas, no brakes: Testosterone may act as 'brake pedal' on immune responseon May 13, 2021 at 11:27 am
Researchers have investigated the role that hormones play in male and female inflammatory responses. In a new study, he found that testosterone may protect against stomach inflammation.
- Research Outlines a Critical Driver in an Immune Cell's Defense against Melanomaon May 11, 2021 at 9:58 pm
Researchers at Huntsman Cancer Institute at the University of Utah report critical new insights into how cells mount an attack against melanoma tumors.
- Personalized vaccine can provide effective immunization against canceron May 11, 2021 at 10:17 am
Marie-Claude Bourgeois-Daigneault and her team at the CRCHUM are using mice to show how a combination of peptides and oncolytic viruses, used as an adjuvant, can provide effective immunization against ...
- Researchers discover regulatory pathway that blocks immune response against canceron May 11, 2021 at 9:57 am
A hallmark of cancer is its ability to evade the immune system. It is why researchers are focused on finding new strategies and targets to jumpstart the immune system so it can mount a response ...
- Moffitt researchers discover regulatory pathway that blocks immune response against canceron May 10, 2021 at 9:00 pm
In a new article published in the journal Immunity, Moffitt Cancer Center researchers show that TIM-3 inhibits the STING signaling pathway in dendritic cells, thereby blocking their ability to elicit ...
- New type of treatment could reawaken immune response against prostate canceron May 10, 2021 at 5:12 am
Targeting a molecule on the surface of immune cells could offer an exciting new way to treat prostate cancer by reawakening the immune response against it.
- PDS Biotech Advances the Fight Against Cancer with its Versamune® Platformon May 3, 2021 at 7:01 am
PDS Biotechnology Corporation (NASDAQ: $PDSB) will be reporting preliminary Phase 2 clinical data of its lead compound PDS0101 for the treatment of advanced HPV-associated ...
- FDA’s ODAC Votes Against Continuation of Pembrolizumab Third-Line Indication in Gastric/GEJ Canceron April 29, 2021 at 12:00 pm
The FDA’s Oncologic Drugs Advisory Committee has voted 6 to 2 against the continued approval of pembrolizumab as indicated for the treatment of patients with recurrent locally advanced or metastatic ...
- Ovarian cancer drug offers new genetically targeted approach against range of cancerson April 24, 2021 at 9:44 am
The results show the exciting potential of PARP inhibitor drugs to be active in PBRM1 deficient tumours, including kidney cancer, as well as for increasing the immune response against these cancers.
- People with blood cancer may not be fully protected against Covid-19 after mRNA vaccines: Studieson April 18, 2021 at 4:46 am
Also Read - Using Cow Dung To Cure Covid-19 Can Turn Dangerous; Doctors Warn However, the researchers highlighted that vaccination against ... cancer treatment showed only 16 per cent immune ...
via Bing News